Hologic Stock

Hologic EV/EBIT

Delisted·Apr 7, 2026

The EV/EBIT (Enterprise Value to EBIT) of Hologic (HOLX) as of Aug 2, 2026 is 23.54. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 19.05 — a change of 23.56% (higher).

EV/EBIT

23.54

YoY

23.56%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Hologic is 2026 23.54 . EV/EBIT (Enterprise Value to EBIT) of Hologic was 2025 19.05 . It decreases by 23.56% higher compared to the previous year.

The Hologic EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
104.78 base
Jan 1, 2020
17.25 base
Jan 1, 2021
7.90 base
Jan 1, 2022
11.37 base
Jan 1, 2023
25.68 base
Jan 1, 2024
18.96 base
Jan 1, 2025
23.56 base
Jan 1, 2026 (e)
14.60 base
YEARPRICE-TO-EBIT
2026 est 14.60
2025 23.56
2024 18.96
2023 25.68
2022 11.37
2021 7.90
2020 17.25
2019 104.78
2018 -41.48
2017 8.76
2016 20.79
2015 24.82
2014 27.07
2013 -6.73
2012 47.40
2011 12.39
2010 70.81
2009 -1.88
2008 -17.10
2007 50.38
2006 51.09
Access this data via the Eulerpool API

Hologic Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Hologic's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Hologic's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Hologic's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Hologic grows earnings faster than its peers.

Hologic Stock analysis

What does Hologic do? Hologic Inc. is a company from the United States that has established itself in the medical technology market. The company was founded in 1985 by Jay A. Stein, who set the goal of developing products and services that contribute to improving people's lives. Hologic specializes in artificial intelligence (AI) based diagnostic and therapeutic technology that increases the safety, effectiveness, and accuracy of medical procedures. The company initially focused on products in the field of mammography, but has since expanded to various sectors including imaging, gynecology, skeletal, and surgery. Hologic offers its customers products such as tomosynthesis systems, robot-assisted surgery systems, image analysis software, and a variety of reagents, kits, and tests. The company's business model is focused on innovative technology and science, aiming to optimize medical interventions and thus reduce and improve healthcare costs. Hologic is dedicated to research and development and has already filed dozens of patents. In the field of breast cancer diagnostics, Hologic has developed various mammography systems that have broken the standard of mammography. Through the use of tomosynthesis, a 3D-based diagnostic, it is possible to detect tumors and malignant changes earlier. This procedure has been widely used by many doctors around the world and has proven to be a reliable method for early detection of breast cancer. In gynecology, Hologic specializes in the development of diagnostic tests for infectious agents and hormones. The tests, such as the Aptima HPV test, are fast, sensitive, and reliable. They help to detect infectious agents earlier and initiate appropriate therapy. Hologic Taurus, a robot-assisted surgery system, has been developed to enable minimally invasive interventions that can be used to treat uterine fibroids. This method allows for a drastic reduction in hospital stay duration and recovery time. In the field of skeletal, Hologic offers various systems that are helpful in the diagnosis and treatment of osteoporosis. The widely used DXA system (Dual-Energy X-Ray Absorptiometer) is still one of the most accurate devices for measuring bone density. Additionally, Hologic is an company that not only focuses on medical technology but also pursues the larger goal of improving people's lives. An example of this is their partnership with the organization Pink Ribbon, which serves as a global ambassador for breast cancer early detection. Hologic has developed a special mammography system called Pink Affirm. For every system sold, Hologic donates a certain amount to Pink Ribbon. Overall, Hologic Inc. has become an important player in the field of medical technology and diagnostics. Through its innovative technologies and products, the company contributes to improving the health and lives of people worldwide. Hologic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hologic stock

EV/EBIT (Enterprise Value to EBIT) of Hologic is 23.54 in 2026.

Access this data via the Eulerpool API

Valuation — Hologic

All Key Metrics — Hologic